Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Position Increased by Orbimed Advisors LLC

Orbimed Advisors LLC grew its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 73.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,227,080 shares of the company's stock after buying an additional 518,680 shares during the period. Orbimed Advisors LLC owned 1.21% of Dyne Therapeutics worth $28,910,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. KBC Group NV boosted its position in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after purchasing an additional 721 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth about $257,000. Magnetar Financial LLC acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $263,000. Finally, E Fund Management Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 11.8% during the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after buying an additional 1,249 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Scotiabank assumed coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target for the company. BMO Capital Markets began coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price for the company. JPMorgan Chase & Co. lowered their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Piper Sandler cut their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, HC Wainwright lowered their target price on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $46.85.

Dyne Therapeutics Stock Up 0.8%

NASDAQ:DYN traded up $0.09 during trading hours on Friday, reaching $11.83. 2,185,589 shares of the stock were exchanged, compared to its average volume of 1,677,802. The stock has a market capitalization of $1.34 billion, a P/E ratio of -3.32 and a beta of 1.19. The firm has a 50 day simple moving average of $10.37 and a 200-day simple moving average of $17.64. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This trade represents a 1.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 6,237 shares of company stock worth $77,760. 14.14% of the stock is currently owned by insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.